VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TEVA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TEVATeva Pharmaceutical Industries Limited
$42.61$50.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. TEVA
  4. Financial Ratios

Teva Pharmaceutical Industries Limited (TEVA) Financial Ratios

Latest Ratios: P/E Ratio 99.6x · EV/EBITDA 22.9x · ROE 20.7%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

TEVA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$50.4B$36.6B$24.9B$11.7B$10.1B$8.9B$10.6B$10.7B$15.7B$19.3B$34.8B
Enterprise Value$64.2B$50.4B$39.7B$28.6B$28.9B$30.2B$34.8B$36.1B$42.9B$50.8B$69.6B
P/E Ratio →99.6326.01———21.08————517.86
P/S Ratio2.932.121.510.740.680.560.630.630.840.861.59
P/B Ratio6.324.634.361.441.180.790.960.711.001.031.00
P/FCF40.7831.8933.2813.879.7237.5716.5625.528.777.318.06
P/OCF30.5722.2019.998.546.3711.118.6919.876.445.496.67

P/E links to full P/E history page with 30-year chart

TEVA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.922.401.811.941.902.092.142.272.273.18
EV / EBITDA22.9415.9752.5218.04—9.90—28.19209.16—18.94
EV / EBIT29.7823.5811.7870.64—9.8011.3913.28——50.76
EV / FCF—43.9353.0133.9827.72127.8054.5386.0623.8919.2816.11

TEVA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin51.8%51.8%48.7%48.2%46.7%47.8%46.4%44.6%44.0%48.4%54.1%
Operating Margin12.5%12.5%-1.8%2.7%-14.7%10.8%-21.4%-2.6%-8.7%-78.1%9.8%
Net Profit Margin8.2%8.2%-9.9%-3.5%-16.4%2.6%-24.0%-5.9%-11.4%-72.7%1.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE20.7%20.7%-23.7%-6.7%-24.7%3.7%-30.5%-6.5%-12.4%-60.5%1.0%
ROA3.5%3.5%-4.0%-1.3%-5.3%0.8%-7.4%-1.7%-3.3%-19.9%0.4%
ROIC7.7%7.7%-1.0%1.2%-5.5%3.8%-7.1%-0.8%-2.6%-21.8%3.1%
ROCE8.0%8.0%-1.0%1.4%-6.4%4.6%-8.8%-1.0%-3.3%-27.5%3.7%

TEVA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity2.202.203.162.482.512.092.391.821.831.731.02
Debt / EBITDA5.505.5023.9112.71—7.70—21.38141.05—9.73
Net Debt / Equity—1.752.582.082.181.892.191.681.721.680.99
Net Debt / EBITDA4.384.3819.5510.67—6.99—19.83132.36—9.46
Debt / FCF—12.0419.7320.1018.0090.2337.9660.5415.1211.978.05
Interest Coverage2.342.343.580.39-2.403.464.052.84-1.88-19.661.03

TEVA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.041.040.981.021.051.140.990.980.960.860.92
Quick Ratio0.800.800.750.690.720.790.650.660.630.580.65
Cash Ratio0.260.260.260.260.240.200.170.140.120.050.05
Asset Turnover—0.420.420.360.340.330.330.290.310.320.24
Inventory Turnover2.622.622.822.042.072.172.032.112.232.352.03
Days Sales Outstanding—78.4567.4978.5190.39104.11100.37122.68112.71116.23125.37

TEVA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————0.5%0.1%4.7%3.7%
Payout Ratio——————————396.0%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield1.0%3.8%———4.7%————0.2%
FCF Yield2.5%3.1%3.0%7.2%10.3%2.7%6.0%3.9%11.4%13.7%12.4%
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.5%0.1%4.7%3.7%
Shares Outstanding—$1.2B$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B$1.0B$1.0B$961M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Leverage Above Two Times Debt-to-Equity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Trailing Multiples Overstate Earnings Power

Based on reported figures, Teva trades at 34.8 times trailing earnings but only 21.0 times forward earnings, a gap that suggests the market expects reported profit to recover from the volatile recent quarters.

The compression from trailing to forward P/E implies that analysts or the market are discounting the most recent net loss of $576M in Q2 2026 as non-recurring rather than structural. EV/EBITDA of 20.0 times compared with 13.6 times forward reflects the same pattern, and a P/B of 6.2 times against an equity base of $8.0B signals that investors are paying a large premium over book value that depends on sustained margin gains. Investors should monitor whether the 16.2 percent operating margin of Q3 2026 repeats before accepting the forward multiple as a reliable anchor.

Leverage Easing Mainly Through Equity Recovery

According to reported quarterly figures, Teva's debt-to-equity ratio fell from 3.16 in Q4 2024 to 2.13 in Q3 2026, while debt-to-EBITDA improved from 75.3 to 17.7 times over the same span.

The improvement in debt-to-equity appears driven more by a rebuilt equity base than by material debt reduction, which means the underlying leverage burden of roughly $17.0B in total debt has changed less than the ratio suggests. Interest coverage has been erratic, swinging between negative readings and 4.1 times within ten quarters, which may indicate that earnings volatility rather than debt scale is the primary constraint on debt service. Refinancing exposure cannot be assessed from the supplied data, so investors should treat the leverage trend as improving but still elevated.

Gross Margin Gains Outrun Operating Results

As reported in the income statements, Teva's gross margin expanded from 48.6 percent in Q2 2024 to 55.5 percent in Q3 2026, yet operating margin has ranged from negative 1.2 to 19.7 percent over the same period.

The gap between gross margin expansion and volatile operating margin suggests that SG&A and R&D spending, or one-time items, are absorbing much of the gross profit improvement. Because the 16.2 percent operating margin in Q3 2026 appears to be an outlier against several negative or near-zero quarters, earning power is better judged from multi-quarter averages than from the latest print. Net margin swings from negative 20.3 to positive 10.2 percent indicate that below-the-line items carry substantial weight in the reported result.

Returns Recovering From Negative Territory

Based on reported figures, Teva's ROIC moved from negative 0.2 percent in Q3 2024 to 2.6 percent in Q3 2026, a recovery that remains thin relative to the company's capital base of roughly $40.0B in total assets.

The return on invested capital remains low in absolute terms, which may indicate that the large goodwill and intangibles balance of $15.7B is diluting returns on the capital actually deployed. ROE of 3.0 percent in the latest quarter, after a period of negative readings, suggests equity recovery has been real but not yet translated into compounding economic returns. Investors should monitor whether ROIC can sustain levels above typical cost of capital before treating the improvement as durable.

Current Ratio Near Parity Under Constraint

According to reported balance sheet data, Teva's current ratio stood at 0.95 and quick ratio at 0.74 in Q3 2026, meaning short-term obligations roughly match current assets with limited margin for error.

A current ratio below 1.0 across most of the ten-quarter window indicates that liquidity relies on continuing operating cash generation rather than a large cushion of liquid assets. With cash of $4.1B against total debt of $17.0B, the position would appear vulnerable under a sharp earnings reversal, though the supplied data does not disclose committed credit facilities that might offset this. Warrants further investigation into maturity schedules before drawing firm conclusions on stress resilience.

Ratio Optics Mask Goodwill-Heavy Returns

Based on the supplied ratio data, the most misapplied metric for Teva is ROE, which looks recovered at 3.0 percent yet is inflated by a thin equity base that sits on top of a $13.7B retained earnings deficit.

Because the equity base of $8.0B is small relative to $17.0B of debt and $15.7B of goodwill, ROE can swing sharply on modest changes in net income and may overstate the economic quality of the recovery. A capital-based measure such as ROIC or return on tangible capital, net of goodwill and intangibles, would better isolate whether the operating business earns above its cost of capital. Investors should weigh tangible-capital returns and free cash flow conversion more heavily than headline ROE when judging durability.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open TEVA Terminal

TEVA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TEVA — Frequently Asked Questions

Quick answers to the most common questions about buying TEVA stock.

What is Teva Pharmaceutical Industries Limited's P/E ratio?

Teva Pharmaceutical Industries Limited's current P/E ratio is 99.6x. The historical average is 31.3x. This places it at the 100th percentile of its historical range.

What is Teva Pharmaceutical Industries Limited's EV/EBITDA?

Teva Pharmaceutical Industries Limited's current EV/EBITDA is 22.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.0x.

What is Teva Pharmaceutical Industries Limited's ROE?

Teva Pharmaceutical Industries Limited's return on equity (ROE) is 20.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 4.6%.

Is TEVA stock overvalued?

Based on historical data, Teva Pharmaceutical Industries Limited is trading at a P/E of 99.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Teva Pharmaceutical Industries Limited's profit margins?

Teva Pharmaceutical Industries Limited has 51.8% gross margin and 12.5% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Teva Pharmaceutical Industries Limited have?

Teva Pharmaceutical Industries Limited's Debt/EBITDA ratio is 5.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.